Established For Non-Sterile API and Pharmaceutical Intermediates, Ningxia Taiyicin Biotech Co., LTD.

Ningxia Taiyicin founded in 2010, covering about 221.73 hectares of construction area with registered capital RMB 625 million, is mainly established for Non-sterile API and pharmaceutical intermediates. The first phase project-3000mt Erythromycin Thiocyanate with total investment of RMB 1.5 billion has reached prospective capacity in Oct,2012. Taiyicin Biotech Co., Ltd. is striving to build itself as a key manufacturing and export base of fermentation APIs and pharma intermediates in China. The main series of products are Lincomycin, Erythromycin and Avermectin. We have started the application of FDA certification.

• Mass Production Plant

Ningxia Taiyicin Biotech Co., Ltd. is a wholly owned subsidiary of Ningxia Tairui Pharmaceutical Co., Ltd. It was established in October 2010. Covering area is about 2.2 km2  with Investment capital USD820 Million.

• Standardized Manufacturing Workshop

Work Shop 105: Tylosin Tartrate/Phosphate raw material Fermentation workshop

Work Shop 203: Tylosin Tartrate/Phosphate raw material Extraction workshop

Work Shop 608: Tilmicosin Base/Phosphate raw material Synthesis workshop

• Complete Marketing System and Channels

Our products mainly export to more than 80 countries, such as Europe, South America, Africa and Asia. Besides satisfying the domestic market, 70% of the products are exported abroad.